Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2015 Apr 23;75(5):1075–1087. doi: 10.1007/s00280-015-2737-4

Fig. 1.

Fig. 1

Peritoneal fluid (a) and plasma (b) paclitaxel concentrations averaged over treatment cycles 1 and 2. Mean peritoneal fluid and mean plasma concentrations are presented per Nanotax® dose level. Error bars ±1 SDEV